{
  "query": "ABBV",
  "resolved": {
    "ticker": "ABBV",
    "cik": "0001551152",
    "title": "AbbVie Inc."
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "AbbVie Inc. (ABBV) — PHASE2 protocol updated 3 days ago",
      "entity": "AbbVie",
      "ticker": "ABBV",
      "cik": "0001551152",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer",
        "nctId": "NCT06820463",
        "date": "2028-03"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT06820463"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06820463",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "AbbVie Inc. (ABBV) — PHASE2 protocol updated 6 days ago",
      "entity": "AbbVie",
      "ticker": "ABBV",
      "cik": "0001551152",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease",
        "nctId": "NCT07599670",
        "date": "2030-04"
      },
      "observed": {
        "event": "protocol updated 6 days ago",
        "nctId": "NCT07599670"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07599670",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "AbbVie Inc.",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-05-12",
        "accession": "0001104659-26-059484",
        "items": "5.07"
      },
      {
        "form": "8-K",
        "date": "2026-04-29",
        "accession": "0001551152-26-000013",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-04-03",
        "accession": "0001551152-26-000011",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-03-04",
        "accession": "0001104659-26-023534",
        "items": "8.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-02-26",
        "accession": "0001104659-26-020643",
        "items": "8.01,9.01"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-06-21T09:50:25.029Z"
}